Obstacles to Early Diagnosis and Treatment of Hidradenitis Suppurativa: Current Perspectives on Improving Clinical Management

References

• Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50–61.
   PubMed Web of Science ®Google Scholar
• McKenzie SA, Harview CL, Truong AK, et al. Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage. Dermatol Online J. 2020;26(9):46.
   Google Scholar
• Jfri A, Litvinov IV, Netchiporouk E, O’Brien E. Clinical and psychosocial factors affecting work productivity among patients with hidradenitis suppurativa: a cluster analytical investigation. J Am Acad Dermatol. 2022;86(3):675–677.
   PubMedGoogle Scholar
• Patel KR, Lee HH, Rastogi S, et al. Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;83(3):737–744.
   PubMed Web of Science ®Google Scholar
• Sorriento D, Iaccarino G. Inflammation and cardiovascular diseases: the most recent findings. Int J Mol Sci. 2019;20(16):3879.
   PubMed Web of Science ®Google Scholar
• Jung JM, Lee KH, Kim YJ, et al. Assessment of overall and specific cancer risks in patients with hidradenitis suppurativa. JAMA Dermatol. 2020;156(8):844–853.
   PubMed Web of Science ®Google Scholar
• Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990–998.
   PubMed Web of Science ®Google Scholar
• Jansen T, Plewig G. What’s new in acne inversa (alias hidradenitis suppurativa)? J Eur Acad Dermatol Venereol. 2000;14(5):342–343.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375(5):422–434.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91–101.
   PubMed Web of Science ®Google Scholar
• Hidradenitis+suppurativa - list results. Home - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=Hidradenitis%2BSuppurativa&term=&cntry=&state=&city=&dist=. Accessed March 15, 2023.
   Google Scholar
• Savage KT, Gonzalez Brant E, Flood KS, Salian P, Porter ML, Kimball AB. Publication trends in hidradenitis suppurativa from 2008 to 2018. J Eur Acad Dermatol Venereol. 2020;34(9):1885–1889.
   PubMed Web of Science ®Google Scholar
• Aarts P, van Huijstee JC, van der Zee HH, van Doorn MBA, van Straalen KR, Prens EP. Adalimumab in conjunction with surgery compared with Adalimumab monotherapy for Hidradenitis suppurativa: a randomized controlled trial in a real-world setting [published online ahead of print, 2023 Apr 27]. J Am Acad Dermatol. 2023;23:S0190–S9622.
   Google Scholar
• Patil S, Apurwa A, Nadkarni N, Agarwal S, Chaudhari P, Gautam M. Hidradenitis Suppurativa: inside and out. Indian J Dermatol. 2018;63(2):91–98.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76–90.
   PubMed Web of Science ®Google Scholar
• Saunte DML, Jemec GBE. Hidradenitis Suppurativa: advances in diagnosis and treatment. JAMA. 2017;318(20):2019–2032.
   PubMed Web of Science ®Google Scholar
• Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk R, Roenigk H, editors. Dermatologic Surgery, Principles and Practice. New York, New York: Marcel Dekker; 1989.
   Google Scholar
• Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546–1549.
   PubMed Web of Science ®Google Scholar
• Blok JL, Boersma M, Terra JB, et al. Surgery under general anaesthesia in severe hidradenitis suppurativa: a study of 363 primary operations in 113 patients. J Eur Acad Dermatol Venereol. 2015;29(8):1590–1597.
   PubMed Web of Science ®Google Scholar
• Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421–430.
   PubMed Web of Science ®Google Scholar
• Kashetsky N, Mukovozov IM, Pereira J, Manion R, Carter S, Alhusayen R. Patient experiences with hidradenitis suppurativa: the Hidradenitis Patient Experience survey. Clin Exp Dermatol. 2022;47(1):72–79.
   PubMed Web of Science ®Google Scholar
• Garg A, Neuren E, Cha D, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366–376.
   PubMed Web of Science ®Google Scholar
• Serrano L, Ulschmid C, Szabo A, Roth G, Sokumbi O. Racial disparities of delay in diagnosis and dermatologic care for hidradenitis suppurativa. J Natl Med Assoc. 2022;114(6):613–616.
   PubMed Web of Science ®Google Scholar
• Sampogna F, Fania L, Mastroeni S, Fusari R, Panebianco A, Abeni D. Quality of life in patients with early- and late-onset hidradenitis suppurativa. Arch Dermatol Res. 2023;315(3):473–479.
   PubMed Web of Science ®Google Scholar
• Barmatz S, Fisch-Gilad S, Hackett A, et al. The bacteriology of skin lesions in patients with hidradenitis suppurativa is associated with previous antibiotic treatment in the community setting: a referral center experience. Dermatology. 2022;238(4):772–784.
   PubMed Web of Science ®Google Scholar
• Ozkur E, Karadag AS, Ustuner P, et al. Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity. Clin Exp Dermatol. 2021;46(3):532–540.
   PubMed Web of Science ®Google Scholar
• Kucinskiene V, Jariene V, Valiukeviciene S. Clinical characteristics of Hidradenitis Suppurativa patients from a reference centre in Kaunas, Lithuania. Dermatology. 2020;236(1):66–70.
   PubMed Web of Science ®Google Scholar
• Loo CH, Tan WC, Tang JJ, et al. The clinical, biochemical, and ultrasonographic characteristics of patients with hidradenitis suppurativa in Northern Peninsular Malaysia: a multicenter study. Int J Dermatol. 2018;57(12):1454–1463.
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Nikolakis G, Kanni T, et al. Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study. Br J Dermatol. 2022;187(3):428–430.
   PubMed Web of Science ®Google Scholar
• Seivright JR, Collier E, Grogan T, et al. Management landscape of pediatric hidradenitis suppurativa. Skin Appendage Disord. 2022;8(2):118–121.
   PubMedGoogle Scholar
• Liy-Wong C, Kim M, Kirkorian AY, et al. Hidradenitis suppurativa in the pediatric population: an international, multicenter, retrospective, cross-sectional study of 481 pediatric patients. JAMA Dermatol. 2021;157(4):385–391.
   PubMed Web of Science ®Google Scholar
• Jfri A, Netchiporouk E, Raymond K, Litvinov IV, O’Brien E. Association of clinical severity scores with psychosocial impact in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2021;84(6):1712–1715.
   PubMed Web of Science ®Google Scholar
• Kirby JS, Miller JJ, Adams DR, Leslie D. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol. 2014;150(9):937–944.
   PubMed Web of Science ®Google Scholar
• Marvel J, Vlahiotis A, Sainski-Nguyen A, Willson T, Kimball A. Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. BMJ Open. 2019;9(9):e030579.
   PubMed Web of Science ®Google Scholar
• Creadore A, Desai S, Li SJ, et al. Insurance acceptance, appointment wait time, and dermatologist access across practice types in the US. JAMA Dermatol. 2021;157(2):181–188.
   PubMed Web of Science ®Google Scholar
• Esme P, Akoglu G, Sari O, Caliskan E. Family physicians’ awareness and general knowledge of hidradenitis suppurativa: a survey research. Int J Clin Pract. 2021;75(7):e14186.
   PubMed Web of Science ®Google Scholar
• Martins DB, Ayanruoh L, Paul M, Shukla N, Naik HB. Hidradenitis suppurativa publications are sparse in frontline specialties. Br J Dermatol. 2020;183(4):770–771.
   PubMed Web of Science ®Google Scholar
• Hidradenitis+Suppurativa - search results - pubmed. National center for biotechnology information. Available from: https://pubmed.ncbi.nlm.nih.gov/?term=hidradenitis%2Bsuppurativa. Accessed March 31, 2023.
   Google Scholar
• 2023 AAD annual meeting. American Academy of Dermatology. Available from: https://www.aad.org/member/meetings-education/am23. Accessed March 31, 2023.
   Google Scholar
• Hidradenitis Suppurativa Foundation. Available from: https://www.hs-foundation.org/. Accessed March 31, 2023.
   Google Scholar
• Koumaki D, Efthymiou O, Bozi E, Katoulis AC. Perspectives on perceived stigma and self-stigma in patients with hidradenitis suppurativa. Clin Cosmet Investig Dermatol. 2019. 12. 785–790.
   PubMed Web of Science ®Google Scholar
• Bilgic A, Fettahlıoglu Karaman B, Demirseren DD, et al. Internalized stigma in Hidradenitis Suppurativa; a multicenter cross-sectional study [published online ahead of print, 2023 Jan 26]. Dermatology. 2023. doi:10.1159/000529194
   PubMedGoogle Scholar
• Happle R, König A. Smoker’s boils. Dermatology. 2011;222(3):282–284.
   PubMed Web of Science ®Google Scholar
• Embuldeniya G, Veinot P, Bell E, et al. The experience and impact of chronic disease peer support interventions: a qualitative synthesis. Patient Educ Couns. 2013;92(1):3–12.
   PubMed Web of Science ®Google Scholar
• Ribero S, Dapavo P, Casalegno C; HS Awareness Working Group. Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light. J Eur Acad Dermatol Venereol. 2019;33(Suppl 6):7–9.
   PubMed Web of Science ®Google Scholar
• De Martino I, D’Apolito R, McLawhorn AS, Fehring KA, Sculco PK, Gasparini G. Social media for patients: benefits and drawbacks. Curr Rev Musculoskelet Med. 2017;10(1):141–145.
   PubMed Web of Science ®Google Scholar
• Househ M, Borycki E, Kushniruk A. Empowering patients through social media: the benefits and challenges. Health Informatics J. 2014;20(1):50–58.
   PubMed Web of Science ®Google Scholar
• Golbari NM, Porter ML, Kimball AB. Online communications among hidradenitis suppurativa patients reflect community needs. J Am Acad Dermatol. 2019;80(6):1760–1762.
   PubMed Web of Science ®Google Scholar
• Roche L, Nic Dhonncha E, Murphy M. TikTok™ and dermatology: promises and pearls. Clin Exp Dermatol. 2021;46(4):737–739.
   PubMed Web of Science ®Google Scholar
• Suarez-Lledo V, Alvarez-Galvez J. Prevalence of health misinformation on social media: systematic review. J Med Internet Res. 2021;23(1):e17187.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747–761.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Zouboulis CC, Sayed C, et al. Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3, randomized, double-blind, placebo-controlled, multicenter studies. Late breaking presentation at: 2023 American Academy of Dermatology (AAD) Annual Meeting; March, 2023; New Orleans, Louisiana.
   Google Scholar
• Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 Adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989–994.
   PubMed Web of Science ®Google Scholar
• Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702–708.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of povorcitinib (INCB054707) in participants with moderate to severe hidradenitis suppurativa - tabular view. A study to evaluate the efficacy and safety of povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa - tabular view - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/record/NCT05620823?term=povorcitinib&cond=Hidradenitis%2BSuppurativa&draw=2&rank=1. Accessed June 11, 2023.
   Google Scholar
• Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe Hidradenitis Suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001–1009.
   PubMed Web of Science ®Google Scholar
• Timila Touhouche A, Chaput B, Marie Rouquet R, et al. Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice. Int J Womens Dermatol. 2020;6(3):164–168.
   PubMedGoogle Scholar
• Meier D. Palliative care as a quality improvement strategy for advanced, chronic illness. J Healthc Qual. 2005;27(1):33–39.
   PubMedGoogle Scholar
• Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for Hidradenitis Suppurativa. Dermatology. 2021;237(1):81–96.
   PubMed Web of Science ®Google Scholar
• Jørgensen AR, Thomsen SF, Ring HC. Clinical phenotypes of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33(3):e111–e112.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292–1298.
   PubMed Web of Science ®Google Scholar
• Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89(6):601–603.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Loesche C, Prens EP, et al. IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and Phase II proof-of-concept study. Exp Dermatol. 2022;31(10):1522–1532.
   PubMed Web of Science ®Google Scholar
• Ring HC, Yao Y, Maul JT, et al. The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study. Br J Dermatol. 2022;187(4):523–530.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Genovese G, Casazza G, et al. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with Adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133–140.
   PubMed Web of Science ®Google Scholar